Live Breaking News & Updates on Prnewswire alar pharmaceuticals inc

Stay informed with the latest breaking news from Prnewswire alar pharmaceuticals inc on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Prnewswire alar pharmaceuticals inc and stay connected to the pulse of your community

Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000

/PRNewswire/ -- Alar Pharmaceuticals Inc. (Alar, TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs)...

Taiwan , Prnewswire-alar-pharmaceuticals-inc , Alar-pharmaceuticals-inc , Alar-pharmaceuticals-inc- ,

Alar Pharmaceuticals Inc.: Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000

Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid

Taiwan , Prnewswire-alar-pharmaceuticals-inc , Alar , Harmaceuticals , Nnounces , Ignificant , Rogress , Eveloping , Ong , Cting , Uprenorphine

Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000

Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting fr...

Taiwan , Prnewswire-alar-pharmaceuticals-inc , Alar-pharmaceuticals-inc ,

Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000

/PRNewswire/ -- Alar Pharmaceuticals Inc. (Alar, TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs)...

Taiwan , Prnewswire-alar-pharmaceuticals-inc , Alar-pharmaceuticals-inc , Alar-pharmaceuticals-inc- ,

Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Taiwan , Prnewswire-alar-pharmaceuticals-inc , Alar-pharmaceuticals-inc , Business , Health , Pr-newswire , Opioids ,

Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000

Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid dependence. TAICHUNG, Taiwan, Jan. 13, 2022 /PRNewswire/ -- Alar Pharmaceuticals Inc. (Alar, TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs) for central nervous system disorders, announces the completion and positive results...

Taiwan , Charles-lin , Prnewswire-alar-pharmaceuticals-inc , Alar-pharmaceuticals , Clinical-opiate-withdrawal-scale , Opioid-craving-visual-analog-scale , Yung-shun-wen ,

Breaking the Cycle of Opioid Addiction: Alar Presents Positive [...] | Comunicati stampa CataniaOggi

10 marzo 2021 09:05
Fonte: Adnkronos
#chimica-e-farmacia
TAICHUNG, March 10, 2021 /PRNewswire/ -- Alar Pharmaceuticals Inc. (TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs) for central nervous system disorders, announces positive interim results from the single-ascending-dose study of ALA-1000. A 3-month buprenorphine released injectable designed to be dosed subcutaneously for treating opioid use disorder (OUD).
The Buprenorphine release from the ALA-1000 single injection lasts over 12 weeks with effective concentrations, showing low initial burst without dose dumping effect and good safety and tolerability, including local skin irritation and injection pain severity.
Opioid dependency: A world health issue
The world-wide opioid epidemic is a documented public health crisis. Treatments for opioid abuse currently rely on Buprenorphine, Methadone, and Naltrexone as Medication-assisted treatment (MAT). However, patients' need to make frequent trips to clinics for oral MAT treatment often leads to relapses or further substance abuse through the switching of one habit for another.

Charles-lin , Prnewswire-alar-pharmaceuticals-inc , Alar-pharmaceuticals , Alar-pharmaceuticals-inc , Shun-wen , Alar-pharmaceuticals-established , Breaking , The , Cycle , Of , Opioid , Addiction

Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients

/PRNewswire/ -- Alar Pharmaceuticals Inc. (TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs) for...

Charles-lin , Prnewswire-alar-pharmaceuticals-inc , Alar-pharmaceuticals , Alar-pharmaceuticals-inc , Shun-wen , சார்லஸ்-லின் , அலார்-மருந்துகள் , அலார்-மருந்துகள்-இன்க் , விலக்கு-வென் ,